• Patient death following CAR-T therapy highlights serious manufacturing issues pharmaceutical-technology
    October 08, 2018
    It is reported that the accidental genetic engineering of a single leukemic cell during the early manufacturing of CAR-T therapy tisagenlecleucel for a phase I study caused the relapse and eventual death of one patient participating in the clinical trial.
  • Sophiris Bio Releases Report on Patient Death americanpharmaceuticalreview
    August 31, 2018
    Sophiris Bio announced the conclusion of the ongoing investigation into the previously reported death of a patient in the company's Phase 2b trial for the treatment of localized prostate cancer is unlikely to be related to either topsalysin or the procedu
  • Patient death sparks safety worries in Ionis trial pharmafile
    May 17, 2017
    Ionis Pharmaceuticals announced the results from a Phase 3 trial of its drug to treat patients with familial amyloid polyneuropathy and the results were extremely positive, except for the side-effects.
PharmaSources Customer Service